# US 2004/0082038 A1 · Glycosylated human granulocyte colony-stimulating factor (G-CSF) isoform

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082038 A1
- Document ID: US20040082038A1
- Status: Published application
- Kind: A1
- Application number: 10/651,395
- Filed: 2003-08-29
- Published: 2004-04-29
- Earliest claimed: 2002-08-31
- Assignees: CJ Corporation
- Inventors: Eun Jung Lee; Hyun Seok Kim; Jong Sang Chung; Ki Wan Kim; Yeon Hyang Kim; Hyune Soo Lee; Hyung Kon Koh; Myung Suk Oh
- Web page: https://patentgrep.com/patent/US20040082038A1

## CPC

- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are human G-CSF isoforms having a modified amino acid sequence containing a glycosylation sequence Asn-X-Ser/Thr (N-X-S/T) at one or more specific amino acid positions according to the present invention, genes encoding the human G-CSF isoforms, and expression vectors carrying the genes, eukaryotic cells transformed or transfected with the expression vectors. Also, the present invention discloses a method of preparing a glycosylated human G-CSF isoform, comprising the steps of culturing the transformant or transfectant and isolating a glycosylated human G-CSF isoform from the culture supernatant or cell lysates, a human G-CSF isoform prepared by the method, and a pharmaceutical composition comprising the human G-CSF isoform.

## Claims

### Claim 1

A human G-CSF isoform having a modified amino acid sequence containing a glycosylation sequence Asn-X-Ser/Thr (N-X-S/T) at one or more amino acid positions as described below:
T1-P10 (T1-P-L-G-P-A-S-S-L-P10);
Y39-L71 (Y39-K-L-C-H-P-E-E-L-V-L-L-G-H-S-L-G-I-P-W-A-P-L-S-S-C-P-S-Q-A-L-Q-L71);
L92-L99 (L92-E-G-I-S-P-E-L99); and
G125-S142 (G125-M-A-P-A-L-Q-P-T-Q-G-A-M-P-A-F-A-S142).

### Claim 2 (depends on 1)

The human G-CSF isoform as set forth in claim 1, wherein the human G-CSF isoform has a modification of the 51st glycine residue to asparagine, of the 94th glycine residue to asparagine, or of the 133rd threonine and 135th glycine residues to asparagine and serine, respectively, or has all of the modifications.

### Claim 3

A gene encoding a human G-CSF isoform having a modified amino acid sequence containing a glycosylation sequence Asn-X-Ser/Thr (N-X-S/T) at one or more amino acid positions as described below:
T1-P10 (T1-P-L-G-P-A-S-S-L-P10);
Y39-L71 (Y39-K-L-C-H-P-E-E-L-V-L-L-G-H-S-L-G-I-P-W-A-P-L-S-S-C-P-S-Q-A-L-Q-L71);
L92-L99 (L92-E-G-I-S-P-E-L99); and
G125-S142 (G125-M-A-P-A-L-Q-P-T-Q-G-A-M-P-A-F-A-S142).

### Claim 4 (depends on 1)

The gene as set forth in claim 1, wherein the human G-CSF isoform has a modification of the 51st glycine residue to asparagine, of the 94th glycine residue to asparagine, or of the 133rd threonine and 135th glycine residues to asparagine and serine, respectively, or has all of the modifications.

### Claim 5 (depends on 3)

A method of preparing a glycosylated human G-CSF isoform, comprising the steps of:
culturing a eukaryotic host cell transformed or transfected with an expression vector carrying the gene encoding a human G-CSF isoform of claim 3; and
isolating the glycosylated human G-CSF isoform from the culture supernatant or cell lysates.

### Claim 6 (depends on 4)

A method of preparing a glycosylated human G-CSF isoform, comprising the steps of:
culturing a eukaryotic host cell transformed or transfected with an expression vector carrying the gene encoding a human G-CSF isoform of claim 4; and
isolating the glycosylated human G-CSF isoform from the culture supernatant or cell lysates.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a glycosylated human G-CSF isoform prepared by additional glycosylation of the human G-CSF isoform of claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 2)

A pharmaceutical composition comprising a glycosylated human G-CSF isoform prepared by additional glycosylation of the human G-CSF isoform of claim 2 and a pharmaceutically acceptable carrier.
